Similar articles

• [Problems and proposals for revision of the Japanese guideline for febrile neutropenia].

  Yoshida M. Yoshida M. Rinsho Ketsueki. 2011 Apr;52(4):182-9. Rinsho Ketsueki. 2011. PMID: 21566403 Review. Japanese. No abstract available.
• High-risk febrile neutropenia in Auckland 2003-2004: the influence of the microbiology laboratory on patient treatment and the use of pathogen-specific therapy.

  Ritchie S, Palmer S, Ellis-Pegler R. Ritchie S, et al. Intern Med J. 2007 Jan;37(1):26-31. doi: 10.1111/j.1445-5994.2006.01239.x. Intern Med J. 2007. PMID: 17199841
• Initial management of febrile neutropenia for the primary provider: a summary of current practice guidelines.

  Delmas A, Hawley J, Berenberg J. Delmas A, et al. Hawaii Med J. 2008 Dec;67(12):333-4. Hawaii Med J. 2008. PMID: 19244707 No abstract available.
• Management of the febrile neutropenic patient.

  Picazo JJ; Association for Health Research and Development (ACINDES). Picazo JJ, et al. Int J Antimicrob Agents. 2005 Dec;26 Suppl 2:S120-2; discussion S133-40. doi: 10.1016/j.ijantimicag.2005.07.010. Epub 2005 Oct 21. Int J Antimicrob Agents. 2005. PMID: 16243492
• Empiric therapy for febrile neutropenia: what are the choices?

  Aoun M. Aoun M. Expert Rev Anti Infect Ther. 2007 Jun;5(3):507-15. doi: 10.1586/14787210.5.3.507. Expert Rev Anti Infect Ther. 2007. PMID: 17547514 Review.